CorMedix Lifts 2026 Revenue Outlook to $325M-$355M
CRMD is trading near its 52-week low of $5.63 (0.3% below the low) on elevated volume (5.7× avg).
Summary
CorMedix now guides fiscal 2026 revenue to $325M-$355M, raising the top end by $10M from the $325M-$345M range it reaffirmed in August. That prior range came alongside Q2 revenue of $101.9M, up 157% year-over-year, so the new ceiling implies continued momentum rather than a reset. The stock sits near its 52-week low of $5.63, so the raise lands against a skeptical tape. The backdrop is mixed: the Q2 10-Q disclosed an unremediated material weakness and an impairment indicator on the oritavancin products, and the company settled a derivative suit over FDA-related disclosures in August. The FDA accepted for filing and granted Priority Review to the REZZAYO prophylaxis sNDA in October, which is the next real swing factor for the revenue line.
At the time of this announcement, CRMD was trading at $5.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $443.9M. The 52-week trading range was $5.63 to $13.02. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.